Based on preclinical and clinical work, the rationale for the RESET-medication randomized double-blind and placebo-controlled trial is to examine the possible beneficial 7-day treatment with the GR antagonist mifepristone (1200 mg per day) in patients with moderate to severe MDD and CT. Here, NR3C1 is linked to major depressive disorder.